AstraZeneca secured ex‑China rights to Jacobio Pharmaceuticals’ clinical pan‑KRAS inhibitor JAB‑23E73 in a deal worth up to $1.915 billion, paying $100 million up front and agreeing to joint development and commercialization in China. Under the agreement, AstraZeneca will lead development, regulatory submissions and commercialization outside China. The transaction gives AstraZeneca a program targeting multiple KRAS mutations, an area of intense oncology competition. Jacobio retains China rights and will receive development and commercial milestones plus tiered royalties. Sources: company releases from Jacobio and AstraZeneca.